‘Omic’ technologies: genomics, transcriptomics, proteomics and metabolomics

Authors Richard P Horgan / Louise C Kenny Key content: • ‘Omic’ technologies are primarily aimed at the universal detection of genes (genomics), mRNA (transcriptomics), proteins (proteomics) and metabolites (metabolomics) in a specific biological sample. • Omic technologies have a broad range of applications. • Genomic and transcriptomic research has progressed due to advances in microarray technology. • Mass spectrometry is the most common method used for the detection of analytes in proteomic and metabolomic research. • Data analysis is complex as a huge amount of data is generated and statistician and bioinformatician involvement in the process is essential. • Much of the omic research in obstetrics and gynaecology has concentrated on using the technology to develop screening tests for gynaecological cancers and obstetric complications.

[1]  Douglas B. Kell,et al.  Novel biomarkers for pre-eclampsia detected using metabolomics and machine learning , 2005, Metabolomics.

[2]  M. Relling,et al.  Moving towards individualized medicine with pharmacogenomics , 2004, Nature.

[3]  Yingyao Zhou,et al.  An Integrated Clinical-Genomics Approach Identifies a Candidate Multi-Analyte Blood Test for Serous Ovarian Carcinoma , 2007, Clinical Cancer Research.

[4]  O. Fiehn,et al.  Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. , 2006, Cancer research.

[5]  Thomas A Trikalinos,et al.  Early extreme contradictory estimates may appear in published research: the Proteus phenomenon in molecular genetics research and randomized trials. , 2005, Journal of clinical epidemiology.

[6]  S. Brennecke,et al.  An emerging role for comprehensive proteome analysis in human pregnancy research. , 2005, Reproduction.

[7]  Thomas A Trikalinos,et al.  Genetic associations in large versus small studies: an empirical assessment , 2003, The Lancet.

[8]  James Lyons-Weiler,et al.  Altered global gene expression in first trimester placentas of women destined to develop preeclampsia. , 2009, Placenta.

[9]  D. Kell,et al.  Here is the evidence, now what is the hypothesis? The complementary roles of inductive and hypothesis-driven science in the post-genomic era. , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[10]  Douglas B Kell,et al.  The virtual human: Towards a global systems biology of multiscale, distributed biochemical network models , 2007, IUBMB life.

[11]  Joseph F. Clark,et al.  Metabolomic analysis of molecular species of phospholipids from normotensive and preeclamptic human placenta electrospray ionization mass spectrometry. , 2004, Frontiers in Bioscience.

[12]  D. Kell,et al.  Detection and Identification of Novel Metabolomic Biomarkers in Preeclampsia , 2008, Reproductive Sciences.

[13]  D. Kell,et al.  Analysis of the metabolic footprint and tissue metabolome of placental villous explants cultured at different oxygen tensions reveals novel redox biomarkers. , 2008, Placenta.

[14]  K. Choy,et al.  Innate immune response by ficolin binding in apoptotic placenta is associated with the clinical syndrome of preeclampsia. , 2007, Clinical chemistry.

[15]  A. Smilde,et al.  Large-scale human metabolomics studies: a strategy for data (pre-) processing and validation. , 2006, Analytical chemistry.

[16]  D. Kell,et al.  Metabolomics by numbers: acquiring and understanding global metabolite data. , 2004, Trends in biotechnology.

[17]  Steven H. Wu,et al.  A proteomic approach identifies early pregnancy biomarkers for preeclampsia: Novel linkages between a predisposition to preeclampsia and cardiovascular disease , 2009, Proteomics.

[18]  J. Fisher,et al.  Plasma From Women with Preeclampsia Has a Low Lipid and Ketone Body Content—A Nuclear Magnetic Resonance Study , 2007, Hypertension in pregnancy.

[19]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[20]  D. Kell.  Systems biology, metabolic modelling and metabolomics in drug discovery and development. , 2006, Drug discovery today.

[21]  B. Ye,et al.  Use of a Combination of Approaches to Identify and Validate Relevant Tumor-Associated Antigens and Their Corresponding Autoantibodies in Ovarian Cancer Patients , 2008, Clinical Cancer Research.

[22]  H. Kurahashi,et al.  Microarray analysis of differentially expressed fetal genes in placental tissue derived from early and late onset severe pre-eclampsia. , 2007, Placenta.

[23]  D. Ransohoff.  Rules of evidence for cancer molecular-marker discovery and validation , 2004, Nature Reviews Cancer.

[24]  D. Kell,et al.  Mass Spectrometry Tools and Metabolite-specific Databases for Molecular Identification in Metabolomics , 2009 .

[25]  R. Romero,et al.  Proteomic analysis of amniotic fluid to identify women with preterm labor and intra-amniotic inflammation/infection: The use of a novel computational method to analyze mass spectrometric profiling , 2008, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[26]  J. Ioannidis.  Contradicted and initially stronger effects in highly cited clinical research. , 2005, JAMA.

[27]  J. Ioannidis,et al.  Evaluation of the potential excess of statistically significant findings in published genetic association studies: application to Alzheimer's disease. , 2008, American journal of epidemiology.

[28]  E. Petricoin,et al.  Clinical proteomics: translating benchside promise into bedside reality , 2002, Nature Reviews Drug Discovery.

[29]  D. Bowtell,et al.  Options available—from start to finish—for obtaining expression data by microarray , 1999, Nature Genetics.

[30]  A. Burlingame,et al.  Functional proteomics: examining the effects of hypoxia on the cytotrophoblast protein repertoire. , 2001, Biochemistry.

[31]  Christian Baumgartner,et al.  Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. , 2008, The Journal of clinical investigation.

[32]  D. Kell,et al.  Changes in the metabolic footprint of placental explant-conditioned culture medium identifies metabolic disturbances related to hypoxia and pre-eclampsia. , 2009, Placenta.

[33]  J. Coorssen,et al.  An initial proteomic analysis of human preterm labor: placental membranes. , 2006, Journal of proteome research.

[34]  W. Dunn,et al.  Measuring the metabolome: current analytical technologies. , 2005, The Analyst.

[35]  G. Mires,et al.  Use of proteomic patterns as a novel screening tool in pre-eclampsia , 2004, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[36]  A. Gadducci,et al.  Serum tumor markers in the management of ovarian, endometrial and cervical cancer. , 2004, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[37]  Yingyao Zhou,et al.  An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  D. Gerhold,et al.  Better therapeutics through microarrays , 2002, Nature Genetics.

[39]  Howard L McLeod,et al.  Cancer pharmacogenomics: current and future applications. , 2003, Biochimica et biophysica acta.

[40]  S. Dasari,et al.  Identification of novel protein biomarkers of preterm birth in human cervical-vaginal fluid. , 2007, Journal of proteome research.

[41]  Douglas B. Kell,et al.  Statistical strategies for avoiding false discoveries in metabolomics and related experiments , 2007, Metabolomics.

[42]  Nigel W. Hardy,et al.  The metabolomics standards initiative (MSI) , 2007, Metabolomics.

[43]  B. Vollenhoven,et al.  Genomics in obstetrics and gynaecology , 2003, The Australian & New Zealand journal of obstetrics & gynaecology.

[44]  A. Vlahou,et al.  Proteomic approaches in the search for disease biomarkers. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[45]  T. Arinami,et al.  Proteome analysis reveals elevated serum levels of clusterin in patients with preeclampsia , 2004, Proteomics.

[46]  B. Palsson,et al.  The evolution of molecular biology into systems biology , 2004, Nature Biotechnology.

[47]  H. Mischak,et al.  Mass spectrometry based proteomics in urine biomarker discovery , 2007, World Journal of Urology.

[48]  Steven A Carr,et al.  Protein biomarker discovery and validation: the long and uncertain path to clinical utility , 2006, Nature Biotechnology.

[49]  R. Romero,et al.  The use of high-dimensional biology (genomics, transcriptomics, proteomics, and metabolomics) to understand the preterm parturition syndrome. , 2008, BJOG : an international journal of obstetrics and gynaecology.

[50]  J. Selbig,et al.  Parallel analysis of transcript and metabolic profiles: a new approach in systems biology , 2003, EMBO reports.

[51]  Wei-Yuan Zhang,et al.  Gene expression profiling of maternal blood in early onset severe preeclampsia: identification of novel biomarkers , 2009, Journal of perinatal medicine.

[52]  I. Blair,et al.  Identification and quantification of preterm birth biomarkers in human cervicovaginal fluid by liquid chromatography/tandem mass spectrometry. , 2009, Journal of proteome research.

[53]  David Baltimore,et al.  Our genome unveiled , 2001, Nature.

[54]  J. Lapidus,et al.  Diagnosis of intra-amniotic infection by proteomic profiling and identification of novel biomarkers. , 2004, JAMA.

[55]  R. Goodacre.  Metabolomics of a superorganism. , 2007, The Journal of nutrition.